Methimazole as First‑Line Therapy for Hyperthyroidism with Isolated Elevated Alkaline Phosphatase

First‑Line Therapy Recommendation

Methimazole is the preferred first‑line antithyroid drug for virtually all adult patients with hyperthyroidism, according to the American College of Endocrinology/American Association of Clinical Endocrinologists (ACE/AACE) guideline. 2

Obtain baseline liver function tests—including bilirubin, transaminases (ALT/AST), and alkaline phosphatase—prior to starting methimazole, as recommended by ACE/AACE. 3
Perform a baseline complete blood count with differential together with the liver profile before therapy, per ACE/AACE guidance. 3

Routine serial liver‑function monitoring is not required in asymptomatic patients; liver tests should be checked only if clinical signs of hepatotoxicity develop, per ACE/AACE. 1
Assess liver function if the patient experiences nausea, fatigue, abdominal pain, jaundice, dark urine, or pale stools, as advised by ACE/AACE. [1][3]
In the presence of such symptoms, obtain an immediate complete blood count with differential and repeat liver‑function testing, per ACE/AACE. 3

Instruct patients to discontinue methimazole immediately and contact their clinician if they develop warning symptoms (e.g., jaundice, dark urine, abdominal pain, nausea, fatigue, fever, pharyngitis, rash). This safety instruction follows ACE/AACE recommendations. [1][3]
Emphasize that these symptoms trigger urgent evaluation, including CBC with differential and liver‑function assessment, as outlined by ACE/AACE. 3

Methimazole should be avoided only in specific circumstances that do not apply to patients with isolated ALP elevation and normal ALT:

PTU is not recommended as first‑line therapy for hyperthyroidism because it carries an unacceptable risk of severe hepatotoxicity, including fatal hepatic necrosis, according to ACE/AACE. 3
PTU should be reserved for first‑trimester pregnancy, thyroid storm, or minor methimazole reactions when definitive therapy (radioactive iodine or surgery) is declined, per ACE/AACE. 1

Initiate methimazole with the goal of achieving euthyroidism within approximately four weeks, as per ACE/AACE guidance. 1
Typical adult dosing is 0.2–0.5 mg/kg per day, following ACE/AACE dosing recommendations. 3
Add a beta‑adrenergic blocker in patients who are older (≈ ≥ 60 years), have a resting heart rate > 90 bpm, have cardiovascular disease, or exhibit symptomatic hyperthyroidism, per ACE/AACE. 1